Welcome to industryreportstore.com

Need help? +44(0)20 7936 6830

Pharmaceuticals market research, reports and industry analysis

mail

Contact us for professional industry advice

Email us or call

+44(0)20 7936 6830
mail

for FREE research alerts
to your inbox

69 Item(s)

Page 1 of 7

  1. Global Drug Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics during the Forecast Period

    By: CBR Pharma Insights
    , Published: Nov-2016
    , Product code: GBI072CBR
    GBI Research’s latest report, "Global Drug Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics during the Forecast Period" discusses the drug delivery technologies and trends in the market and the evolving business strategies being adopted and leveraged by companies globally. The ultimate goal of drug delivery research is to develop formulations and devices that can be used in clinical applications to treat various diseases. Delivering a drug with the desired release kinetics requires an understanding of the underlying physicochemical properties of the drug, which determine the type of delivery material and drug release mechanism. Numerous parameters need to be considered, and their inter-dependence has to be taken into account to develop successful drug delivery systems for the intended applications. It is important to understand the complexity associated with the development of a drug delivery system that can ultimately be used in human patients. The report covers the currently available drug delivery technologies and recent advances in the field, with granular analyses of the different types of delivery systems, their advantages, disadvantages and opportunities for future development. The report provides global market forecasts by revenue for the market until 2020. Additionally, forecasts by revenue for key geographical markets and supporting analyses of the main factors driving or restraining growth are included. The market for drug delivery technology is poised for strong growth in the coming years. Key factors promoting growth include the rapidly expanding injectables market, the growing incidence of chronic diseases and the expected significant increase in the use of complex biologic drugs that necessitate novel delivery systems. Drug delivery companies have had to adapt to challenging times in the same way as pharmaceutical companies have had to over the past decade. These companies have achieved this by adopting new business strategies that allow them to take better control of their commercial and financial future. The report analyzes how business models in this dynamic industry have evolved over the last couple of decades and how new companies with improved product portfolios and propositions are emerging.
    $2,995.00

  2. Strategic Trends in Private Equity and Venture Capital Funding for Healthcare

    By: CBR Pharma Insights
    , Published: Nov-2016
    , Product code: GBI073CBR
    GBI Research’s latest report, "Strategic Trends in Private Equity and Venture Capital Funding for Healthcare" provides a comprehensive analysis on emerging investment trends within the healthcare industry. Private equity (PE) and venture capital (VC) funds have been important participants in a wide range of industries for many decades - particularly the healthcare industry. They remain one of the few sources of funding for innovative start-up companies, which often bring disruptive technologies and life-saving medical interventions to the market.
    $2,995.00

  3. The Future of Generic Drugs and Strategies for Commercial Success

    By: CBR Pharma Insights
    , Published: Sep-2016
    , Product code: GBI074CBR
    GBI Research’s latest report “The Future of Generic Drugs and Strategies for Commercial Success” discusses trends in the global generic drugs market, and the evolving business strategies being adopted and leveraged by generic drug companies around the world. GBI Research conducted an extensive and targeted industry survey of experts from top global generic drug companies, to gather opinions on the trends and future commercial prospects of the generic drugs market. The findings from the survey and results from extensive data analysis and secondary research efforts have been triangulated with GBI’s own analytical views to provide an objective assessment that is comprehensive in outlook.
    $2,995.00

  4. Innovation Tracking Factbook 2016 - An Assessment of the Pharmaceutical Pipeline

    By: CBR Pharma Insights
    , Published: Jun-2016
    , Product code: GBI067CBR
    GBI Research’s latest report, "Innovation Tracking Factbook 2016 - An Assessment of the Pharmaceutical Pipeline" is a comprehensive, granular analysis of the 20,756 products currently in the pharmaceutical industry pipeline, from the Discovery stage through to Pre-registration and split into therapy areas and key indications. This pipeline is also benchmarked against its size across each segment in 2015, and an assessment of the level of first-in-class innovation is provided. In addition, a detailed contextual analysis of the key drivers of this pipeline is provided, in addition to an assessment of companies present in the pipeline and historical deal value and volume.
    $2,995.00

  5. Human Drugs For Veterinary Use - Current Trends and Future Commercial Prospects for Crossover Drugs

    By: CBR Pharma Insights
    , Published: May-2016
    , Product code: GBI069CBR
    GBI Research's latest report, "Human Drugs For Veterinary Use - Current Trends and Future Commercial Prospects for Crossover Drugs", discusses global commercial trends and prospects for human medicines applied in the veterinary setting, also called crossover drugs. A wide range of human drugs continue to be applied in the veterinary space due to a lack of approved animal therapies, convenience and the rising costs of veterinary research.
    $2,995.00

  6. Substance Abuse Deterrents and Treatments - An Assessment of the Technological, Competitive and R&D Landscape

    By: CBR Pharma Insights
    , Published: Mar-2016
    , Product code: GBI066CBR
    GBI Research's latest report, "Substance Abuse Deterrents and Treatments - An Assessment of the Technological, Competitive and R&D Landscape", discusses global trends in the substance abuse deterrents and addiction treatments market including the impact substance abuse is having on local economies, healthcare systems and society as a whole. This new report provides analyses of current unmet medical needs as well as an in-depth review and assessment of technologies being employed by pharmaceutical manufacturers to reduce the risk of prescription drug misuse and abuse. A series of detailed case studies showcase novel abuse deterrent formulations (ADFs) that have been recently adopted by manufacturers of commonly abused prescription drugs. Although these technologies are relatively nascent, we expect the ADF field to grow rapidly in the coming years driven by strong demand and local government support within many key markets.
    $2,995.00

  7. Telehealth: Global Market Trends, Regulatory Landscape and Operational Strategies

    By: CBR Pharma Insights
    , Published: Mar-2016
    , Product code: GBI071CBR
    GBI Research's latest report, "Telehealth: Global Market Trends, Regulatory Landscape and Operational Strategies", provides key insights into the global telehealth regulatory and market landscape, as well as its main applications in healthcare and associated sectors.
    $2,995.00

  8. Evolving Market Access Strategies - Pricing and Reimbursement Landscape in Major Developed Pharmaceutical Markets

    By: CBR Pharma Insights
    , Published: Jan-2016
    , Product code: GBI070CBR
    GBI Research's latest report, "Evolving Market Access Strategies - Pricing and Reimbursement Landscape in Major Developed Pharmaceutical Markets" assesses developments within the key elements of market access such as Health Economics and Outcome Research (HEOR), Health Technology Assessment (HTA) as well as pricing and reimbursements strategies for pharmaceutical products. This new report also discusses the need to integrate market access strategies earlier into the drug development process, in order to save time and costs related to conducting additional studies to prove the added benefits of a product. Additionally, our new study analyses the role of HTAs in market access and alternatives that could be used in cases where there is limited evidence. Detailed analysis of pricing and reimbursement policies in North America, five key European countries and Japan are also included in this report along with a myriad of relevant case studies. In order to gain optimum market access, companies have to analyze the economic benefit of the treatment, the level of competition and the required reimbursement support.
    $2,995.00

  9. The OTC Drugs Market: Commercial Trends and Rx-to-OTC Switch Prospects

    By: CBR Pharma Insights
    , Published: Dec-2015
    , Product code: GBI064CBR
    GBI Research’s latest report, "The OTC Drugs Market: Commercial Trends and Rx-to-OTC Switch Prospects" discusses trends in the over-the-counter (OTC) pharmaceuticals market and the commercial prospects for switching drugs from prescription-only to OTC status. The report assesses current market drivers and restraints, mergers and acquisitions (M&A) activity and recent regulatory developments in key national markets. Furthermore, this report analyses leading therapeutic segments in the OTC drugs market, key brands, manufacturers and the potential for new product categories to be created as more prescription-only drugs from diverse therapy areas continue to be considered for OTC approval. Detailed case studies of recent Rx-to-OTC switches provide the rationale for these switches including description of their economic and financial impact.
    $2,995.00

  10. Biobanking: Developing Smart, Sustainable and Ethically Compliant Biorepositories for the Future

    By: CBR Pharma Insights
    , Published: Dec-2015
    , Product code: GBI063CBR
    GBI Research’s latest report, "Biobanking: Developing Smart, Sustainable and Ethically Compliant Biorepositories for the Future" discusses fundamental concepts in biobanking and recent technology advancements in the field. The report also describes ethical and regulatory concerns in biobanking as well as the economic challenges and opportunities surrounding this industry. Furthermore, this report provides strategic recommendations on how to overcome some of the most critical economic, technological and ethical challenges facing this fast-growing sector.
    $2,995.00

69 Item(s)

Page 1 of 7